TRAX (First Tracks Biotherapeutics) Total Current Liabilities: $36.18 Mil (As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Total Current Liabilities?

First Tracks Biotherapeutics TRAX +11.85% 12 Total Current Liabilities is $36.18 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. First Tracks Biotherapeutics's total current liabilities for the quarter that ended in Dec. 2024 was $36.18

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

First Tracks Biotherapeutics Total Current Liabilities Related Terms

First Tracks Biotherapeutics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Total Current Liabilities Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Total Current Liabilities
18.22 36.18

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Total Current Liabilities 18.22 36.18
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

First Tracks Biotherapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=26.839+1.925
+Other Current Liabilities+Current Deferred Liabilities
=7.419+0
=36.18

First Tracks Biotherapeutics's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=26.839+1.925
+Other Current Liabilities+Current Deferred Liabilities
=7.419+0
=36.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $36.18 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Total Current Liabilities of $36.18 Mil as of Dec. 2024. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Total Current Liabilities too high?
First Tracks Biotherapeutics' current Total Current Liabilities is $36.18 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Total Current Liabilities compare to ALT and RGNX?
First Tracks Biotherapeutics' Total Current Liabilities of $36.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Total Current Liabilities is $36.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Total Current Liabilities of $36.18 Mil. The current Total Current Liabilities is $36.18 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Total Current Liabilities is $36.18 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price